Prediction of blood-brain barrier penetration of poorly soluble drug candidates using surface activity profiling

European Journal of Pharmaceutics and Biopharmaceutics

Volumn 75, Issue 3, 2010, Pages 405-410

  Petereit, Anna Christine ^a   Swinney, Kelly ^b   Mensch, Jurgen ^b   Mackie, Claire ^b   Stokbroekx, Sigrid ^b   Brewster, Marcus ^b   Dressman, Jennifer B ^a  

^a GOETHE UNIVERSITY   (Germany)

^b JANSSEN RESEARCH FOUNDATION   (Belgium)

Author keywords

Blood brain barrier; Cross sectional area; Drug discovery; Gibbs adsorption isotherms; Maximum surface pressure; Surface activity profiling

Indexed keywords

2 HYDROXYPROPYL BETA CYCLODEXTRIN;

ANIMAL EXPERIMENT; AQUEOUS SOLUTION; ARTICLE; BLOOD BRAIN BARRIER; CORRELATION ANALYSIS; DISSOCIATION CONSTANT; DRUG PENETRATION; DRUG SOLUBILITY; DRUG TRANSPORT; MALE; MOLECULAR WEIGHT; NONHUMAN; PARTITION COEFFICIENT; PH; RAT; SURFACE ACTIVITY PROFILING; SURFACE PROPERTY; SURFACE TENSION;

ANIMALS; BLOOD-BRAIN BARRIER; MALE; PHARMACOKINETICS; RATS; RATS, SPRAGUE-DAWLEY; SOLUBILITY; SURFACE TENSION;

EID: 77954541068     PISSN: 09396411     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejpb.2010.03.015     Document Type: Article

References (28)

1. Fu X.C., Chen C.X., Liang W.Q., Yu Q.S. Predicting blood-brain barrier penetration of drugs by polar molecular surface area and molecular volume. Acta Pharmacol. Sin. 2001, 22(7):663-668.
2. Begley D.J. Delivery of therapeutic agents to the central nervous system: the problems and the possibilities. Pharmacol. Ther. 2004, 104(1):29-45.
3. Abraham M.H., Takacs-Novak K., Mitchell R.C. On the partition of ampholytes: application to blood-brain distribution. J. Pharm. Sci. 1997, 86(3):310-315.
4. Ingels F., Deferme S., Destexhe E., Oth M., Van den Mooter G., Augustijns P. Simulated intestinal fluid as transport medium in the Caco-2 cell culture model. Int. J. Pharm. 2002, 232(1-2):183-192.
5. Di L., Kerns E.H., Fan K., McConnell O.J., Carter G.T. High throughput artificial membrane permeability assay for blood-brain barrier. Eur. J. Med. Chem. 2003, 38(3):223-232.
6. Palm K., Stenberg P., Luthman K., Artursson P. Polar molecular surface properties predict the intestinal absorption of drugs in humans. Pharm. Res. 1997, 14(5):568-571.
7. van de Waterbeemd H., Camenisch G., Folkers G., Chretien J.R., Raevsky O.A. Estimation of blood-brain barrier crossing of drugs using molecular size and shape, and H-bonding descriptors. J. Drug Target 1998, 6(2):151-165.
8. Lipinski C. Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Adv. Drug Deliv. Rev. 1997.
9. van de Waterbeemd H.e.a. Hydrogen-bonding capacity and brain penetration. Chimia 1992, 46:299-303.
10. Parsons D.S. Biological Membranes: Twelve Essays on their Organization, Properties, and Functions 1975, Clarendon Press, Oxford [Eng.].
11. Pauletti G.M., Okumu F.W., Borchardt R.T. Effect of size and charge on the passive diffusion of peptides across Caco-2 cell monolayers via the paracellular pathway. Pharm. Res. 1997, 14(2):164-168.
12. Seelig A. The use of monolayers for simple and quantitative analysis of lipid-drug interactions exemplified with dibucaine and substance P. Cell Biol. Int. Rep. 1990, 14(4):369-380.
13. Seelig A., Gottschlich R., Devant R.M. A method to determine the ability of drugs to diffuse through the blood-brain barrier. Proc. Natl. Acad. Sci. USA 1994, 91(1):68-72.
14. Seelig A. Local anesthetics and pressure: a comparison of dibucaine binding to lipid monolayers and bilayers. Biochim. Biophys. Acta 1987, 899(2):196-204.
15. Boguslavsky V., Rebecchi M., Morris A.J., Jhon D.Y., Rhee S.G., McLaughlin S. Effect of monolayer surface pressure on the activities of phosphoinositide-specific phospholipase C-beta 1, -gamma 1, and -delta 1. Biochemistry 1994, 33(10):3032-3037.
16. Fischer H., Gottschlich R., Seelig A. Blood-brain barrier permeation: molecular parameters governing passive diffusion. J. Membr. Biol. 1998, 165(3):201-211.
17. Gerebtzoff G., Seelig A. In silico prediction of blood-brain barrier permeation using the calculated molecular cross-sectional area as main parameter. J. Chem. Inf. Model 2006, 46(6):2638-2650.
18. Brewster M.E., Anderson W.R., Estes K.S., Bodor N.S., Pop E., Panetta J.A. Tissue distribution of LY231617, an antioxidant with neuroprotectant activity, in the rat. J. Pharm. Sci. 1995, 84(7):791-793.
19. Mensch J., Noppe M., Adriaensen J., Melis A., Mackie C., Augustijns P., Brewster M.E. Novel generic UPLC/MS/MS method for high throughput analysis applied to permeability assessment in early drug discovery. J. Chromatogr. B Analyt. Technol. Biomed. Life Sci. 2007, 847(2):182-187.
20. pION-techNOTE, Double-Sink™ PAMPA: High Throughput GI Absorption for the 21st Century, vol. P021018-2, 2006. http://www.pion-inc.com.
21. Kansy M., Senner F., Gubernator K. Physicochemical high throughput screening: parallel artificial membrane permeation assay in the description of passive absorption processes. J. Med. Chem. 1998, 41(7):1007-1010.
22. Suomalainen P., Johans C., Soderlund T., Kinnunen P.K. Surface activity profiling of drugs applied to the prediction of blood-brain barrier permeability. J. Med. Chem. 2004, 47(7):1783-1788.
23. Mattila J.P., Sabatini K., Kinnunen P.K. Oxidized phospholipids as potential novel drug targets. Biophys. J. 2007, 93(9):3105-3112.
24. Gerebtzoff G., Li-Blatter X., Fischer H., Frentzel A., Seelig A. Halogenation of drugs enhances membrane binding and permeation. Chembiochem 2004, 5(5):676-684.
25. Schott H. Saturation adsorption at interfaces of surfactant solutions. J. Pharm. Sci. 1980, 69(7):852-854.
26. Rosen M.J. Surfactants and Interfacial Phenomena 1989, John Wiley Sons.
27. Liu H., Sabus C., Carter G.T., Du C., Avdeef A., Tischler M. In vitro permeability of poorly aqueous soluble compounds using different solubilizers in the PAMPA assay with liquid chromatography/mass spectrometry detection. Pharm. Res. 2003, 20(11):1820-1826.
28. Kelder J., Grootenhuis P.D., Bayada D.M., Delbressine L.P., Ploemen J.P. Polar molecular surface as a dominating determinant for oral absorption and brain penetration of drugs. Pharm. Res. 1999, 16(10):1514-1519.